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Glial cell line-derived neurotrophic factor (GDNF) is absolutely required for survival of dopaminergic (DA) nigrostriatal neurons and
protect them from toxic insults. Hence, it is a promising, albeit experimental, therapy for Parkinson’s disease (PD). However, the source
of striatal GDNF is not well known. GDNF seems to be normally synthesized in neurons, but numerous reports suggest GDNF production
in glial cells, particularly in the injured brain. We have studied in detail striatal GDNF production in normal mouse and after damage of
DA neurons with MPTP. Striatal GDNF mRNA was present in neonates but markedly increased during the first 2–3 postnatal weeks.
Cellular identification of GDNF by unequivocal histochemical methods demonstrated that in normal or injured adult animals GDNF is
expressedby striatal neurons and is not synthesized in significant amounts by astrocytes ormicroglial cells.GDNFmRNAexpressionwas
not higher in reactive astrocytes than in normal ones. Approximately 95% of identified neostriatal GDNF-expressing cells in normal and
injured animals are parvalbumin-positive (PV) interneurons, which only represent0.7%of all striatal neurons. The remaining 5%of
GDNF cells are cholinergic and somatostatin interneurons. Surprisingly, medium spiny projection neurons (MSNs), the vastmajor-
ity of striatal neurons that receive a strong DA innervation, do not express GDNF. PV interneurons constitute an oscillatory functional
ensemble of electrically connected cells that control MSNs’ firing. Production of GDNF in the PV neurons might be advantageous to
supply synchronous activity-dependent release ofGDNF inbroad areas of the striatum. Stimulation of theGDNF-producing striatal PV
ensemble in PD patients could have therapeutic effects.
Introduction
The glial cell line-derived neurotrophic factor (GDNF) is a potent
dopaminotrophic agent that promotes survival, differentiation,
and phenotype of neurons. GDNF protects dopaminergic nigro-
striatal neurons from neurotoxins in rodents and primates, and
induces fiber outgrowthwhen administered into the brain paren-
chyma (Tomac et al., 1995; Gash et al., 1996; Kordower et al.,
2000). GDNF has also a neuroprotective effect on noradrenergic
neurons of the rodent locus ceruleus (Arenas et al., 1995; Pascual
et al., 2008). Based on these data, stimulation of endogenous
GDNF production and/or exogenous GDNF administration
are considered promising therapeutic strategies for Parkinson’s
disease (PD) (Kirik et al., 2004; Pascual et al., 2008). Indeed, the
clinical effectiveness of intrastriatal infusion of recombinant
GDNF has been evaluated in open (Gill et al., 2003) and double-
blind (Lang et al., 2006) clinical trials. Intrastriatal transplantationof
GDNF-producing cells has also been tested in parkinsonian ani-
mals (Akerud et al., 2001; Toledo-Aral et al., 2003) and humans
(Arjona et al., 2003; Mínguez-Castellanos et al., 2007).
Clinical applicability of GDNF, still in an experimental stage,
will surely benefit from refinement of the method of delivery in
parallel with advances in the knowledge of GDNF function in the
normal and injured brain (Check, 2007; Vastag, 2010). In this
regard, the recent demonstration that adult nigrostriatal dopami-
nergic neuron survival is absolutely dependent on striatal GDNF
production should stimulate future therapeutic developments in
the field (Iba´n˜ez, 2008; Pascual et al., 2008). However, the actual
source of striatal GDNF is, surprisingly, not known in detail.
GDNF is present in several parts of the brain (mainly striatum,
thalamus, and septum) and is normally expressed in neurons
(Pochon et al., 1997; Trupp et al., 1997), but the nature of striatal
neurons responsible for GDNF synthesis is not fully character-
ized (Bizon et al., 1999). Moreover, GDNFmRNA is detected in
cultured astrocytes andmicroglia, but whether the trophic factor
is produced in relevant amounts in vivo by these cell types has not
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been precisely evaluated (Saavedra et al., 2008). It has been re-
ported that GDNF expression increases under brain injury due to
recruitment of GDNF-synthesizing glial cells (astrocytes and mi-
croglia), which may eventually become the predominant source
of the trophic agent (Hughes et al., 1999; Bresjanac and Antauer,
2000). Nonetheless, this concept is under debate and the actual
role of reactive glia in GDNF production in vivo is unsettled
(Saavedra et al., 2008).
The objective of this work was to investigate brain GDNF
expression in mice, with special emphasis in the identification
of the striatal cell (neuron or glia) population producing
GDNF. We have studied several genetically modified mouse
models to precisely identify the sites of GDNF synthesis. These
mice were used in combination with MPTP-treated animals to
evaluate in vivo GDNF production by reactive glia. Our data
show an unexpected pattern of striatal GDNF expression,
linked to the organization and function of the GABAergic
synchronous interneuron ensemble. The findings suggest that
stimulation of endogenous GDNF-secreting cells could be a
feasible methodology of potential clinical relevance.
Materials andMethods
Mice (C57BL/6N strain) were housed under temperature-controlled
conditions (22°C) in a 12 h light/dark cycle with access ad libitum to food
and water. All experiments were performed according to institutional
guidelines approved by the ethics committee of the Hospital Universita-
rio Virgen del Rocio and the European Community (Council Directive
86/609/EEC). Heterozygous GDNF-LacZ mice of either sex and out-
crossed to C57BL/6N background for 10 generations (Sa´nchez et al.,
1996) were used for analysis of the pattern of GDNF expression in neo-
nates (P0; i.e, up to 24 h after birth), and at P8, P17, and adulthood (2
months old). GDNF promoter activity was estimated by -galactosidase
enzymatic detection in brains from heterozygous GDNF-LacZ mice
(Sa´nchez et al., 1996; Villadiego et al., 2005). Transgenic GDNF-EGFP
mice of either sex were obtained from GENSAT on a mixed background
(Gong et al., 2003). Animals were killed either by administration of chlo-
ral hydrate anesthesia (490mg/kg) (adult mice) or by decapitation (neo-
natal animals).
Histological analyses. Mouse brain was re-
moved from anesthetized animals and imme-
diately fixed overnight (15 h; adult mice) or 4 h
(neonatal mice) at 4°C with 4% paraformalde-
hyde in PBS. Brains included in gelatin were
cut in 50-m-thick coronal sections using a
vibratome (Leica). For the histological detec-
tion of GDNF expression, we used heterozy-
gous GDNF-LacZ mice (Sa´nchez et al., 1996)
and the 5-bromo-4-chloro-3-indolyl--D-
galactopyranoside (X-gal)-staining, or GDNF-
EGFP, mice (Gong et al., 2003) and
immunohistochemistry forGFP. In either case,
a wild-type animal was used as a negative con-
trol in all the experiments. For colocalization
studies, immunohistochemistry was per-
formed with the appropriate antibody after
X-gal staining or GFP immunohistochemistry.
The Envision kit (Dako) was used for chro-
matic immunohistochemistry according to the
recommended manufacturer’s protocol. Pri-
mary antibodies used were as follows: anti-
NeuN (1:200; Millipore Bioscience Research
Reagents); anti-choline acetyltransferase
(ChAT) (1:1000; Millipore Bioscience Re-
search Reagents); anti-SS (1:800; Millipore);
anti-GFP (monoclonal, 1:100; Roche); anti-
IBA1 (1:500;Wako); anti-tyrosine hydroxylase
(TH) (1:5000; Novus Biologicals); anti-PV28
(1:6000; Swant); anti-glial fibrillary acid
protein (1:500; Dako); anti-GFP (polyclonal, 1:1000; Invitrogen); anti-
DARPP32 (1:200, Millipore; and 1:50, Santa Cruz Biotechnology); anti-
calbindin (CB) (1:10,000: Swant); and anti-CR (1:8000; Swant). For GFP
detection in colocalization studies, we used either mouse (monoclonal)
or rabbit (polyclonal) anti-GFP antibodies. In general, the latter pro-
vided a stronger signal. Secondary antibodies anti-rabbit or anti-mouse
were added in a second step and the reaction was developed with 3,3-
diaminobenzidine (Dako). For the immunofluorescent studies, we used
secondary antibodies anti-mouse IgG or anti-rabbit conjugated with Al-
exa Fluor 488 or Alexa Fluor 568 (1:800; Invitrogen).
Stereological cell counts. Quantification of GDNF expression in
brains of MPTP-treated and control heterozygous GDNF-LacZ mice
was done by counting the total number of cells containing X-gal dots.
We counted parvalbumin (PV)-, somatostatin (SS)-, and ChAT-
immunopositive neurons in 50-m-thick coronal sections with a vi-
bratome using the C.A.S.T. (Computer Assisted Stereological
Toolbox) system (Olympus). Cells positive for both markers (immu-
nohistochemistry and X-gal) were estimated in the caudate–putamen
nucleus following Franklin and Paxinos (2008), using 205–273 ran-
Figure 1. GDNF expression in neostriatum of neonatal and adult mice. A–D, GDNF promoter activity estimated by in situ
-galactosidase enzymatic detection from GDNF-LacZ mouse brain slices. Blue X-gal precipitate is indicated by arrows. Coronal
sections through the neonatal (P0) (A, B) and adult (P55) (C, D) striatum are shown at low (A, C) and high (B, D) magnification.
Scale bars: A, C, 100m; B, D, 20m. Tomake visible GDNF expression at lowmagnification (C) a blue dot was drawn over each
X-gal-positive cell (see inset).E, Relative striatalGDNFmRNA levels estimatedbyqRT-PCR inneonatal (P0, blackbar), juvenile (P15,
dark gray bar), and adult (P55, light gray bar) mice. Data (relative to P55) are represented as mean SEM (n 8 for each age
group). **p 0.01).
Table 1. GDNF expression in neonatal (P0) and adult (P55) mouse brain
Structure
Postnatal day
Neonatal (P0) Adult (P55)
Olfactory bulb  
Septum  
Striatum  
Accumbens nucleus, core  
Accumbens nucleus, shell  
Striatal–pallidal border  
Thalamus  
Hypothalamus  
Substantia nigra  
Subcommissural organ  
Interpeduncular nucleus  
Retrorubral field  
Oculomotor nucleus  
Motor trigeminal nucleus  
Locus ceruleus  
The study is based on seven brains from GDNF-LacZmice analyzed per age and structure., No X-gal-positive cell
found; , 1–10 GDNF-positive cells/analyzed structure; , 10–50 GDNF-positive cells/analyzed structure;
,50 GDNF-positive cells/analyzed structure.
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dom 14,260 m2 dissectors. Values are given
as mean SEM and relative to the total pro-
portion of each cell type in the striatum
(Tepper and Bolam, 2004).
Acute MPTP treatment. Heterozygous,
2-month-old, wild-type GDNF-LacZ or GFAP-
EGFP mice were rendered parkinsonian by a
single subcutaneous administration (40 mg/
kg) ofMPTP (Sigma).Micewere killed 7, 14, or
21 d after the lesion, and their brains were pro-
cessed for immunohistochemistry, cell sorting,
or real-time PCR analysis.
Quantitative real-time PCR. Total striatal
levels of GDNF mRNA were determined by
quantitative real-time PCR (qRT-PCR) in con-
trols (P0, P15, and adult mice) and MPTP-
injured mice (7, 14, and 21 d after lesion).
Striatal RNA was extracted using 300 l of
TRIzol reagent (Invitrogen) in a homogenizer
(Omni TH). RNA samples (0.5 g) were
treated with RNase-free DNase (GE Health-
care) and copied to cDNA using SuperScriptII
reverse transcriptase (Invitrogen) in a final vol-
ume of 20l. Real-time PCRwas performed in
an Applied Biosystems Prism 7500 Sequence
Detection System using TaqMan Gene Expres-
sion Master Mix (Applied Biosystems). In the
case of mice with MPTP treatment, Actb and
GapdhRNA levels were estimated to normalize
for RNA input amounts. A Taqman probe for
hydroxymethylbilane synthase (HMBS) gene
was used to normalize RNA levels in P0, P15,
and adultmice. This gene has been shown to be
a bona fide unvaried transcript for quantitative
PCR studies of brain genes with low expression
levels (Sieber et al., 2010). Two different Taq-
Man probes were used for estimation ofGDNF
mRNA levels (exon 1–2 and exon 2–3), and the
values obtained were pooled together. To nor-
malize mRNA levels in treated/aged mice to
control samples, we calculated an average cycle
threshold of the control samples and processed
all the samples in the experiment relative to this
average cycle threshold. Primers and Taqman
sequences are available upon request.
Isolation of GFAP striatal cells. Briefly, we
dissected the striatum from the brain ofGFAP-
EGFP mice (Zhuo et al., 1997) without lesion
and 7, 14, or 21 d after MPTP administration.
The dispersed striatal cells were resuspended in
medium containing (for 50ml): 44ml L15me-
dium (Invitrogen), 0.5ml of penicillin/streptomycin (Cambrex), 0.1 g of
BSA (Sigma), 0.05 ml of HEPES (Invitrogen), and 5 ml of distilled and
deionized water. Dead cells (7-AAD) were eliminated from sorts and
analyses. GFP-positive and -negative striatal subpopulations were iso-
lated in aMoFlo three-laser flow cytometer (Dako and Cytomation) and
processed for qRT-PCR analysis.
Statistics. Data are presented as the mean  SEM and were analyzed
with one-way ANOVA followed by Tukey’s test. A p value 0.05 was
considered statistically significant.
Results
Postnatal changes of GDNF expression in mouse brain
We evaluated the level of GDNF expression in neonatal (P0) and
adult (P55) animals using a semiquantitative methodology, as
determined by the number of X-gal-positive deposits in different
brain areas of the GDNF-LacZmouse. The activity of the GDNF
promoter was estimated using -galactosidase as reporter (Sa´n-
chez et al., 1996; Toledo-Aral et al., 2003). In this animal model,
previously used by our group to characterize brain regions with
strong GDNF mRNA and protein expression (Pascual et al.,
2008), -galactosidase activity is only found in the sites of GDNF
expression in adult brain, as described by using radioactive in situ
hybridization (Trupp et al., 1997). We observed a clear change of
brain GDNF expression pattern with postnatal maturation (Ta-
ble 1), thus indicating that in addition to its role in organ andPNS
development, GDNF acquires new neurotrophic functions in
adult life. Interestingly, GDNF expression was practically absent
fromneonatal caudate-putamen (Fig. 1A,B,E), although a signif-
icant increase of GDNF mRNA level was observed soon (P15)
during postnatal maturation (Fig. 1E). In young adults (P55),
cells expressing GDNF were sparsely, but rather uniformly, dis-
tributed in the neostriatum (Fig. 1C,D). These observations fur-
ther demonstrate that GDNF is highly expressed in the adult
Figure 2. Selective neuronal GDNF expression in adult mouse striatum. A–C, Striatal coronal sections from GDNF-LacZmouse
showing GDNF expression (X-gal staining, blue dots indicated by white arrowheads) and neurons (A, NeuN), astrocytes (B,
GFAP), and microglia (C, IBA1) cell types (black arrowheads). D–F, Confocal microscopy Z-stacks of striatal coronal sections
fromGDNF-EGFPmouse. GDNFexpression is revealedwith an antibody against GFP (D,green), and astrocytes are detectedbyGFAP
immunofluorescence (E, red). Nuclei are shown in blue (DAPI staining), and a merged image is shown in F. Scale bars, 20m.
Figure 3. GDNF expression after MPTP treatment is restricted to striatal neurons. A, D, Low magnification of coronal brain
sections showing a strong striatal astrogliosis in MPTP-treated animals 7 (A) and 21 (D) d after injury (d.a.i). B, E, Striatal areas
inside the squares in A and D are shown at higher magnification to demonstrate that the X-gal cells (blue dots indicated by
arrowheads) arenotGFAPastrocytes.C,F, Striatal IBA1-positive cells donot expressGDNF (X-gal staining, bluedots indicatedby
arrowheads) in MPTP-lesioned (7 and 21 d.a.i.) animals. LV, Lateral ventricle. Scale bars: A, D, 200m; B, C, E, F, 10m.
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striatum (Trupp et al., 1997; Bizon et al., 1999; Pascual et al.,
2008), and support its neurotrophic function on the dopaminer-
gic nigrostriatal and mesolimbic pathways. During embryonic
development, GDNF is not necessary for maintenance of mesen-
cephalic dopaminergic neurons, as these cells are unaffected in
GDNF-null animals (Moore et al., 1996; Sa´nchez et al., 1996). The
neurotrophic role of GDNF seems to be acquired later in life, prob-
ablyonceGDNF-producingcells arephenotypicallymatured inpar-
allel with the postnatal development of the dopaminergic
nigrostriatal system (Burke, 2003) (see Identification of GDNF-
expressing striatal neurons, below).
GDNF expression in normal and
injured adult striatum is confined to
neurons and is practically absent from
glial cells
To ascertain the cell types expressing
GDNF in the normal brain, we stained
brain sections from GDNF-LacZ animals
with antibodies against neuronal (NeuN),
astroglial (GFAP), and microglial (IBA1)
markers. Of 150 striatal X-gal deposits
analyzed (14 sections from three animals),
all were found in neurons. In striatal sec-
tions stained with antibodies against ei-
therGFAP (33 sections from4 animals) or
IBA1 (26 sections from 6 animals), we
have never detected any X-gal deposit in
these types of glial cells. This typical distri-
bution was found in the striatum (Fig.
2A–C) aswell as in other brain areas (thal-
amus and septum) expressing GDNF
(data not shown). The lack of GDNF in
normal neostriatal astrocytes was further
confirmed using brain sections from
GDNF-EGFP mice (Gong et al., 2003)
costained with antibodies against GFAP
(Fig. 2D–F). These data indicated that in
normal brain, GDNF is mostly confined
to neurons and is absent from or ex-
pressed at low levels in glial cells.
As it has been proposed that GDNF production increases
upon brain damage (Hanbury et al., 2003), mainly due to up-
regulation of the GDNF gene in glial cells (Hughes et al., 1999;
Bresjanac and Antauer, 2000; Saavedra et al., 2008), we studied
GDNF expression in GDNF-LacZ animals treated with a single
MPTP dose to induce partial or complete destruction of dopami-
nergic nigrostriatal neurons (Mejías et al., 2006). These animals,
examined 7–21 d afterMPTP injection, exhibited a characteristic
strong striatal astroglial reaction (Figure 3A,D). However, the
Figure 4. Striatal astrocytic GDNFmRNA expression does not increase after MPTP treatment. A, Striatal GDNFmRNA levels estimated by qRT-PCR from total striatum of control (black bar) and
MPTP-treatedwild-typemice [gray bars; 7, 14, and 21 d after injury (d.a.i.)]. No significant differences were observed ( p 0.051, one-way ANOVA, Tukey’s test).B, Left, Flow cytometry diagrams
showing astrocyte separation by cell sorting from striata of untreated (control) and MPTP-treated (21 d.a.i.) GFAP-EGFPmice. The diagrams show the increase of GFAP-EGFP-positive cells in the
striatumafterMPTP treatment (R2 increased from61.29 to 80.72%). Center,GFAPmRNA is enriched in the isolated population (EGFP) as shownby RT-PCR. TheGAPDHgenewas used as a loading
control. Right, AstrocyticGDNFmRNA levels estimatedbyqRT-PCR from isolatedEGFP cells of untreated (blackbar) andMPTP-treated (graybars; 7, 14and21d.a.i.)GFAP-EGFPmice.Data [relative
units (r.u.) to untreated group] are represented as mean SEM; n 4–8.
Figure5. GDNF is not expressed in striatalmediumspinyprojectionneurons.A, Striatal coronal sections fromGDNF-LacZmouse
showing absence of GDNF expression (X-gal staining, blue dots) in MSNs (DARPP32). B, High magnification of A. The white
arrowhead points to a blue dot in close apposition to a DARPP32 neuron. C, Confocal microscopy Z-stacks showing that
DARPP32MSNs (red)were not X-gal (green).D–F, Striatal slices fromGDNF-EGFPmouse stainedwith fluorescent antibodies
against DARPP32 and GFP (polyclonal). Note the lack of overlapping between the two signals. The planes of C and Dwere slightly
adjusted to make the cells appear into focus.
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pattern ofGDNF expression remained unchangedwith respect to
the one in normal animals. None of the X-gal deposits examined
(n  2946 in three animals) appeared in either astrocytes
(GFAP) (Fig. 3B,E) or microglial (IBA1) cells (Fig. 3C,F).
GDNFmRNA levels were alsomeasured in the striatum removed
from MPTP-injured animals by qRT-PCR. In accord with the
data obtained with the X-gal technique, lesioned animals showed
an increase of GDNFmRNA expression that reached a peak and
then declined over the weeks after MPTP injection (Fig. 4A).
Three weeks after the lesion, we still observed a nonsignificant
1.5-fold increase of striatalGDNFmRNAwith respect to controls
(p  0.051, one-way ANOVA). To further investigate whether
brain damage specifically induces GDNF in astrocytes, we per-
formed experiments in MPTP-treated GFAP-EGFP mice (Zhuo
et al., 1997) in which striatal astrocytes (GFAP-EGFP) can be
efficiently separated by flow cytometry. As illustrated in Figure
4B, MPTP treatment induced a relative 30% increase of the
GFAP cell population (R2 gate) as a consequence of the reac-
tive astrocytosis shown before (Fig. 3). However, in this enriched
astrocyte population GDNF mRNA levels were similar to those
measured in unlesioned animals (Fig. 4B). Altogether, these find-
ings strongly suggest that striatal GDNF production increases
moderately in response to damage of the dopaminergic nigrostri-
atal neurons. However, glial cells, particularly astrocytes whose
number is strongly increased in lesioned animals, do not seem to
be a significant source of GDNF. Therefore, the data support the
view that striatal neurons, and not glial cells, are the predominant
sites of GDNF production in normal and injured animals.
Identification of GDNF-expressing striatal neurons
Medium spiny projecting neurons (MSNs) represent 90–95% of
the rodent striatal neurons, being the remaining cells in a mixed
population of interneurons (Tepper and Bolam, 2004). Among
these, a small percentage (0.3% of all striatal neurons) com-
prises cholinergic interneurons, and the rest are GABAergic in-
terneurons. GABAergic interneurons are further divided into
several neurochemically distinct classes. Approximately 0.7% of
all striatal neurons are interneurons that express the calcium
binding protein PV (Tepper and Bolam, 2004). The other popu-
lations of GABAergic interneurons express CB, calretinin (CR),
or SS (Gerfen et al., 1985; Kawaguchi, 1993; Rymar et al., 2004).
Using selectivemarkers to identify the various neuronal subtypes
indicated above, we analyzed by immunohistochemistry striata
ofGDNF-LacZ animals. It was surprising that projection neurons
(DARPP32), the most abundant in the striatum that receive a
strong innervation fromnigrostriatal dopaminergic cells (Tepper
et al., 2010), were never seen to contain X-gal aggregates (Fig.
5A,B). Apparent colocalization of X-gal deposits with DARPP32
cells observed in some cases, was not confirmed by confocal anal-
yses (Fig. 5B,C). This findingwas also supported by analyzing the
GDNF-EGFP mouse, in which DARPP32 cells (examined in
nine striatal sections from three animals) never colocalized with
GFP neurons (Figure 5D–F).
Among the population of striatal interneurons, X-gal expres-
sion was seen in 83% of PV GABAergic interneurons. Qualita-
tively, GDNF expression was demonstrated both in GDNF-LacZ
animals (X-gal deposits) (Fig. 6A–C) and in GDNF-EGFPmice,
as well as with the two differentGFP antibodies used (Fig. 6D–F).
Although in smaller proportion (6% and 3%, respectively),
GDNF expression was also observed in cholinergic interneurons
(ChAT), a population of large aspiny cells sparsely but evenly
distributed throughout striatum (Fig. 7A,B) as well as in SS
(Fig. 7C,D) interneurons. In contrast, GDNF signals were absent
in CB or CR cells (Fig. 7E,F). The quantitative summary of
neostriatal GDNF expression (Fig. 8A) indicates that among the
population of identified GDNF (X-gal) cells, 95% were
PV. The remainingGDNF-expressing cells were either ChAT
(3%) or SS (4%). This distribution of GDNF-synthesizing in-
terneurons remained essentially unaltered in striatum from
MPTP-treated animals studied 7 d after injury (Fig. 8A). There-
fore, the data indicate that both in normal conditions and after
toxic damage of dopaminergic nigrostriatal neurons in adult
mouse, PV GABAergic interneurons are the main neostriatal
source of the GDNF necessary for maintenance and survival of
the nigrostriatal system. Appearance of striatal GDNF (delayed to
the initial P10–P15) (Fig. 1) parallels the ontogenic maturation
of PV neurons, which starts in the lateral striatum at approxi-
Figure 6. Expression of GDNF in PV interneurons of adult striatum. A, B, Striatal coronal sections from GDNF-LacZ mouse showing GDNF expression (X-gal staining, blue dots) in PV
interneurons. The square in A is shown at high magnification in B. Black arrowheads indicate neurons positive for X-gal and PV. C, Confocal microscopy Z-stacks showing a PV interneuron (red)
that is X-gal (green). D–F, Confocal microscopy Z-stacks of striatal slices from GDNF-EGFPmouse. GDNF-EGFP neurons (D, green) also express PVmarker (E, red). A merged image is shown in
F. Scale bars, 10m. In D–F, we used a mouse (monoclonal) anti-GFP antibody. Highly visible GFP expression was also seen with the GFP polyclonal antibody (data not shown).
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mately P9 in rodents (Schlo¨sser et al., 1999). At this stage (Fig. 8B,
top), GDNF neurons are observed in the region where PV ex-
pression initiates but overcome in number the PV cells. This
suggests that GDNF synthesis could precede PV expression dur-
ing interneuron postnatal maturation. Nonetheless, at P18 the
number of PV cells expressing GDNFwas similar to that found
in adult striatum (Fig. 8B, bottom).
Discussion
In the last decade, GDNF-based therapies have become a promise
for the treatment of PDbecause of the potent trophic effect of this
agent on dopaminergic neurons both in vitro (Lin et al., 1993)
and in vivo (Tomac et al., 1995). It has also recently been demon-
strated thatmaintenance of themouse dopaminergic adult nigro-
striatal system absolutely depends on neostriatal GDNF
production (Pascual et al., 2008), although the source of GDNF
is not well known. The design of new GDNF-based therapeutic
approaches for PD would surely benefit from a more precise
knowledge of endogenous GDNF function in the normal and
injured brain. In this article, we show that GDNF production in
mouse striatum develops in early postnatal life and is essentially
confined to neurons. We have not detected large amounts of
GDNF in glial cells either in normal animals or after damage of
the nigrostriatal pathway. In both circum-
stances, GDNF is absent from the densely
innervated striatalMSNs and appears pre-
dominantly expressed in PVGABAergic
interneurons.
As other neurotrophic factors, GDNF
is normally expressed in low quantities,
and its identification by means of stan-
dard immunohistochemical methods is
hampered by the lack of highly specific
antibodies and the low level of expression
of the protein (Villadiego et al., 2005;
Lonka-Nevalaita et al., 2010). We have
overcome this limitation using the GDNF-
LacZmouse (Sa´nchez et al., 1996), which
permits unequivocal identification of
GDNF-expressing cells. We have shown
before in several cell types a close relation-
ship betweenGDNF promoter activity (as
evidenced by X-gal histochemistry) and
GDNF synthesis and release (Villadiego et
al., 2005). Critical observations on GDNF
expression were also confirmed using the
GDNF-EGFP mice (Gong et al., 2003) or
by qRT-PCR of highly enriched glial cell
populations obtained by cell sorting from
striata ofGFAP-EGFP transgenic animals.
Therefore, the main conclusions in this
article are based on data obtained with
various animal models and complemen-
tary methodologies.
In accord with previous reports
(Trupp et al., 1997; Pascual et al., 2008),
we have further confirmed that the thala-
mus, septum, nucleus accumbens, and
neostriatum show the highest levels of
GDNF expression in the adult brain (Ta-
ble 1). Striatal GDNF is practically absent
in neonates, but appears during the sec-
ond to third postnatal weeks, and its pro-
duction remains during adulthood (Fig. 1;
Table 1). This temporal pattern coincides with postnatal matu-
ration of the nigrostriatal pathway (Antonopoulos et al., 2002;
Burke, 2003) and striatal PV neurons (Schlo¨sser et al., 1999;
Chesselet et al., 2007), the ones that show the highest expression
of GDNF in adult mouse (see below). Neonatal mesencephalic
dopaminergic neurons are normal in the GDNF-null animals
(Moore et al., 1996; Sa´nchez et al., 1996); therefore, it seems that
their trophic dependence on this factor develops early after birth
in parallel with the maturation and phenotypic specification of
dopaminergic nigrostriatal axon terminals and their targets in the
striatum. If the same process occurs in humans, one could spec-
ulate that subtle developmental alterations produced during this
critical time period could eventually result in higher susceptibil-
ity to parkinsonism in adulthood.
In normal brain, GDNF was found in significant quantities in
striatal neurons rather than in astrocytes or microglia (Fig. 2). In
glial cells,GDNFmRNAwas amplified by RT-PCR, but the pres-
ence of the trophic factor was not observable using either the
GDNF-LacZ or the GDNF-EGFP mice (Figs. 2–4). Although
there is an abundant literature on the glial expression of GDNF,
our findings are in accord with reports suggesting that in central
and peripheral neuronal tissues GDNF is normally confined to
Figure7. Selective expression of GDNF in ChAT- and SS-positive GABAergic interneurons of adult striatum.A,B, Striatal coronal
sections from GDNF-LacZmouse showing GDNF expression (X-gal, blue dots indicated by arrowheads) in ChAT interneurons. B,
Confocal microscopy Z-stacks analysis of ChAT interneurons. Arrowhead indicates the X-gal precipitate. C–F, Striatal coronal
sections from GDNF-LacZ mouse showing GDNF expression (X-gal, blue dots) in SS (C, D) but not in CR (E) or CB (F )
GABAergic interneurons.D, Confocalmicroscopy Z-stacks analysis of SS interneurons. Arrowheads indicate theX-gal precipitate.
Scale bars, 10m.
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neurons (Pochon et al., 1997; Bizon et al.,
1999). In this regard, it is worth mention-
ing that, similar to the brain, GDNF ex-
pression in the adult carotid body, a
neuronal crest-derived organ of the pe-
ripheral nervous system that contains
high levels of this trophic factor (Toledo-
Aral et al., 2003; Pardal et al., 2007), ap-
pears in neuron-like glomus cells rather
than in the glia-like sustentacular type II
cells (Villadiego et al., 2005). As reported
before (Hanbury et al., 2003; Saavedra et
al., 2008), striatal GDNF expression was
upregulated in response to toxic injury of
dopaminergic nigrostriatal neurons, but,
surprisingly, this appeared to be a conse-
quence of increased GDNF production in
neurons rather than in glial cells. Al-
though inMPTP-lesioned animals we ob-
served a clear increase in the number of
striatal astrocytes and microglia, evidence
of GDNF-LacZ transcriptional activity
was seen only in neurons. Furthermore,
qRT-PCR analyses of enriched astrocyte
populations did not indicate an increase
of GDNF expression in reactive glia (stud-
ied 7–21 d after lesion) in comparison
with controls. These findings clearly con-
tradict a common view, albeit not ac-
cepted by all authors, that GDNF
production switches fromneurons to glial
cells in the damaged brain (Saavedra et al.,
2008). They could also question, at least in
terms of quantitative significance, the pu-
tative neuroprotective action of activated
glia. Nonetheless, the current study fo-
cuses on the MPTP-injured nigrostriatal
system, and, therefore, its conclusions
cannot be extended to other models in
which astrocytic GDNF production has
been proposed to have a neuroprotective
role (Saavedra et al., 2008).
Our data indicate that the most abun-
dant sources of neostriatal GDNF, either
in normal or MPTP-lesioned animals, are
GABAergic PV interneurons that repre-
sent 0.7% of neostriatal neurons but
95% of all GDNF-expressing cells identified in this structure.
The remaining GDNF-expressing cells were SS and ChAT
interneurons (Figs. 5–8). MSNs, the most abundant population
in the striatum that receive themajority of the nigral dopaminer-
gic afferent fibers were never seen to show X-gal marks or GFP
expression indicative of GDNF promoter activity. The fact that
MSNs do not seem to contribute to the retrograde neurotrophic
support of the nigrostriatal system is an unexpected finding that
suggests adaptive specializations within the striatal connectome
(Fig. 8C, scheme). PV interneurons are sparsely distributed
over the striatum, and its distribution obeys a ventral-to-dorsal,
medial-to-lateral, and caudal-to-rostral gradient of increasing
density. This striatal topology coincides with the area innervated
by dopaminergic terminals from the substantia nigra (Bjo¨rklund
and Dunnett, 2007). PV interneurons receive dopaminergic
inputs from the substantia nigra and glutamatergic synapses
from thalamus and cortex. Their axons generate powerful prox-
imal inhibitory synapses ontoMSNs. As in other parts of the CNS
(i.e., cortex or hippocampus), striatal PV neurons are “fast-
spiking” cells capable of sustaining high-frequency (400 Hz)
action potential firing with little afterhyperpolarization or spike
frequency adaptation. PV cells constitute a unique network
interconnected by electrical synapses due to dendrodendritic gap
junctions, which enable them to fire almost synchronously. Stri-
atal fast-spiking PV cells can resonate at the gamma frequency
(Sharott et al., 2009) and are considered to be the major compo-
nent of a powerful feedforward inhibition that controls spike
timing in MSNs, thereby regulating striatal output (Gittis et al.,
2010; Tepper et al., 2010; Chuhma et al., 2011). GDNF produc-
tion in PV neurons could be advantageous if the trophic factor
is released during periods of activity of the cell functional ensem-
ble (Lonka-Nevalaita et al., 2010), thus interacting with axon
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Figure8. A, Quantitative summaryof neostriatal GDNF-expressing interneurons. Percentageof identifiedX-gal-positive cells in
striatum from normal animals (black bars) and from MPTP-treated mice 7 d after injection (gray bar). B, Parallel appearance of
GDNF and PV in striatal interneurons during postnatal maturation. Representative striatal coronal sections from P9 (top) and P18
(bottom)GDNF-LacZmice showingGDNF (X-gal staining) andPV (brown color) expression. Arrowheads indicate X-gal blue dots. C,
Simplified scheme of the striatal connectome. Axons of MSNs (green) send collaterals to neighboring MSNs. These cells are under
control of parvalbuminGABAergic interneurons (red), a cell ensemble synchronized throughmultiple dendrodendritic electrical
synapses (resistances in the scheme). Glutamatergic cortical and thalamic inputs to PVs and MSNs are indicated in gray color.
Dopaminergic nigrostriatal fibers (yellow) innervate both PVs and MSNs. Retrograde GDNF signaling supporting trophic mainte-
nance of dopaminergic neurons is represented by blue discontinuous lines and the halus surrounding the GDNF-producing PV
interneurons.
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terminals of practically the entire nigrostriatal pathway. Addi-
tional advantages that PV interneurons could offer as the
source of neurotrophic support for the nigrostriatal pathway re-
sult from their presumable high resistance to excitotoxicity, due
to the cytosolic content of parvalbumin (a powerful Ca2 buff-
ering protein) and because repetitive electrical firing depends on
Na rather than on Ca2 currents (Tepper et al., 2010). Meta-
bolic demands in “fast-spiking” interneurons appear to be coped
with through the expression of particularly high levels of oxida-
tive phosphorylation enzymes (Gulya´s et al., 2006). In addition to
PV cells, the other GDNF-producing interneurons might also
have a role in the maintenance of projection or local striatal cir-
cuits. SS and ChAT interneurons, although less numerous
than PV cells, could contribute to nigrostriatal trophic support
since they also receive dopaminergic innervation. On the other
hand, exogenous GDNF administration seems to protect MSNs
in models of Huntington’s disease (Alberch et al., 2002). Thus, it
could be that in normal conditions GDNF dependent trophic
support is provided by cholinergic interneurons, which receive
axon collaterals of MSNs (Tepper et al., 2010).
Identification of the ensemble of PV interneurons as the
main source of striatal GDNF raises numerous questions of po-
tential clinical relevance. Neuroprotection in PD has been at-
tempted so far by continuous administration of exogenous
GDNF released locally in the striatum. If endogenous GDNF se-
cretion is actually associated with the synchronized electrical ac-
tivity of striatal PV cells, it would imply that, in physiologic
conditions, the trophic factor is simultaneously released in
broad areas of the striatum and with a pulsating or discontin-
uous time course, circumstances that probably help optimize
its neurotrophic actions. In this sense, it is worthy to remark
that the number of neostriatal interneurons in primates is
higher than in rodents (Tepper and Bolam, 2004). Therefore,
stimulation in PD patients of the striatal PV cell population
(e.g., by pharmacological, electric, or magnetic means) to syn-
thesize and release GDNF under controlled conditions could
have therapeutic effects.
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